Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement ...

Immuneering said investors agreed to buy roughly 6.3 million shares of its Class A common stock for $3.95 a piece. In lieu of Class A common stock, certain investors will buy pre-funded warrants to ...

Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% ...

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotechnology company specializing in oncology treatments, announced ...

US stocks in the Dow Jones, Nasdaq, and S&P dropped at the US market open on 21 August 2025, as investors exercised caution ...

Dr. Zeskind discusses how Immuneering’s treatments can impact a broad range of cancer types. Dr. Ben Zeskind, CEO and co-founder of Immuneering, spoke with Pharmaceutical Executive about his company’s ...

View the latest Immuneering Corp. (IMRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.